Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Growth in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 215,700 shares, an increase of 35.4% from the October 31st total of 159,300 shares. Based on an average daily volume of 670,800 shares, the short-interest ratio is currently 0.3 days. Approximately 0.6% of the shares of the company are short sold.

Hedge Funds Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd lifted its holdings in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 51,660 shares of the company’s stock after acquiring an additional 36,441 shares during the period. XTX Topco Ltd owned approximately 0.13% of Achilles Therapeutics worth $42,000 as of its most recent filing with the SEC. 56.38% of the stock is currently owned by institutional investors and hedge funds.

Achilles Therapeutics Price Performance

Shares of Achilles Therapeutics stock opened at $1.07 on Friday. Achilles Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.76. The firm has a fifty day moving average price of $1.01 and a two-hundred day moving average price of $0.89. The company has a market cap of $43.98 million, a PE ratio of -0.65 and a beta of 1.35.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.